CClinicalTrials.gg
RecruitingNCT02418832Updated Mar 4, 2025

Testis Needle Aspiration of Sperm in Men With Azoospermia

An interventional study of Sperm cell aspiration and TEFNA in Azoospermia, sponsored by Hadassah Medical Organization. Recruiting at 1 site in Israel. Open to male participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-04.

Sponsored by Hadassah Medical Organization · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
16 Years to 80 Years
Sex
Male
01

Study summary

Needle aspiration of the epididymis causes rupture and irreversible damage to the duct. Recurring punctures and needle aspirations of fluid and tissue during Testicular Fine Needle Aspiration (TEFNA) procedure cause irreparable injury and loss of part of the testis' tubules. The hypothesis of this research is that production of sperm from the testis will be improved due to ultrasonically guided Rete Testis needle aspiration. In cases of Obstructive Azoospermia, the Rete Testis is expected to contain a large number of sperm cells. In cases of Non-Obstructive Azoospermia, the investigators can expect to produce sperm cells from aspiration of the Rete Testis, which drains all of the testis' tubules. Furthermore, catheterization of the Rete Testis will allow for the drainage of all testes tubules and for the production of sperm cells created locally in some of the tubules or in parts of them.

The potential advantage of needle aspiration from the Rete Testis is that the procedure will allow for the aspiration from all the testes tubules, as opposed to the standard method of sperm cells production from the testis which samples only some of the tubules. Therefore, it is expected that the procedure suggested in this research will be more efficient than the standard procedures currently in practice. An additional advantage to this procedure is that puncture and aspiration of the tubule network is not expected to block the drainage from the testis, as is the case in aspiration of the epididymis, and it is also not expected to damage the tubules, as is the case in TEFNA and in TESE.

Read the detailed description

Potential subjects will be Azoospermic men who turn to the IVF unit at Hadassah Ein Kerem and are candidates for a TEFNA treatment.

Only after the men will receive an explanation of the TEFNA procedure and sign a consent form for TEFNA will they be invited to join the study.

After an explanation, the men will sign a consent form (attached) for participation in the study.

The TEFNA procedure in each testis will begin with an ultrasonically guided Rete Testis needle aspiration and washing of the testes tubules. A PP Spinal Needle, of 20-27 Gage and 90mm length, will be used for the ultrasonically guided puncture of the testis and catheterization of the Rete Testis network. After the catheterization, there will be an aspiration, followed by the washing of the testis tubule network in saline used for IV, in a volume of up to 1mL (5), using a 1mL syringe. In men with Obstructive Azoospermia, in case the samples aspirated from the Rete Testis will contain many motile sperm cells (more than hundreds), there will be no need for a TEFNA procedure. In cases where an initial sample of the Rete Testis aspiration will not show many motile sperm cells, the TEFNA procedure will continue on as planned.

The samples from the Rete Testis aspiration will be separately checked for sperm cells from the sample and tissue produced from the TEFNA procedure. The sperm cells produced from the Rete Testis will be used for cryopreservation or fertilization of the ovum of the patient's partner, as is customary in sperm cells attained through the TEFNA procedure. Should sperm cells be produced both from the Rete Testis and from the epididymis or testes, the partner's ovum will be fertilized by the highest quality sperm cells of both sources.

Clinical follow-up on patients will be conducted as customary after testis aspiration.

The patients will be invited six months after the procedure for an ultrasonic check-up of the testes and the Rete Testis.

02

Conditions studied

  • Azoospermia

Browse trials for

Keywords

  • Azoospermia
  • Rete Testis
  • TEFNA
03

Who can participate

Ages eligible
16 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • Men with Obstructive/Non-Obstructive Azoospermia who turned to sperm cell aspiration for IVF and were found suitable for TEFNA and signed consent form.

Exclusion criteria

Exclusion Criteria:

  • healthy, non-azoospermic men
  • men who are unsuitable for the TEFNA procedure
  • men who don't sign the Informed Consent
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Other
    Men with Azoospermia, sperm cell aspiration and TEFNA

    Men between 16-80 with Obstructive and Non-Obstructive Azoospermia; Sperm cell aspiration,TEFNA and Ultrasound Guidance

    Procedure: Sperm cell aspiration and TEFNA

Interventions

  • ProcedureSperm cell aspiration and TEFNA

    Testicular Fine Needle Aspiration (TEFNA)

05

What researchers measure

Primary outcomes

  1. Ultrasound Guidance of Sperm Aspiration to Improve Efficiency of TEFNA

    The efficiency will be assessed by the percentage of participants in which at least one sperm cell will be successfully retrieved from ultrasound-guided Rete-Testis aspiration. The efficiency will be calculated separately for participants with Obstructive- and non-Obstructive Azoospermia.

    Time frame: 5 years

06

Study locations

1 of 1 sites recruiting
  • Hadassah University Medical Center, Ein Kerem
    Jerusalem, 9112100, Israel
    Recruiting
07

References and documents

Publications

  • Schoysman R, Van Roosendaal E, Bollen N, Vandervorst M, Vanderzwalmen P, Standaert V, Berting G, Debauche C, Lefere C. Modern sperm retrieval techniques and their usefulness in oocyte fertilization. BJU Int. 2001 Jul;88(2):141-6. doi: 10.1046/j.1464-410x.2001.02301.x. No abstract available. PubMed 11446872 ↗
  • Lewin A, Reubinoff B, Porat-Katz A, Weiss D, Eisenberg V, Arbel R, Bar-el H, Safran A. Testicular fine needle aspiration: the alternative method for sperm retrieval in non-obstructive azoospermia. Hum Reprod. 1999 Jul;14(7):1785-90. doi: 10.1093/humrep/14.7.1785. PubMed 10402390 ↗
  • Friedler S, Raziel A, Strassburger D, Soffer Y, Komarovsky D, Ron-El R. Testicular sperm retrieval by percutaneous fine needle sperm aspiration compared with testicular sperm extraction by open biopsy in men with non-obstructive azoospermia. Hum Reprod. 1997 Jul;12(7):1488-93. doi: 10.1093/humrep/12.7.1488. PubMed 9262283 ↗
  • Schlatt S, Rosiepen G, Weinbauer GF, Rolf C, Brook PF, Nieschlag E. Germ cell transfer into rat, bovine, monkey and human testes. Hum Reprod. 1999 Jan;14(1):144-50. doi: 10.1093/humrep/14.1.144. PubMed 10374111 ↗
  • Hermann BP, Sukhwani M, Winkler F, Pascarella JN, Peters KA, Sheng Y, Valli H, Rodriguez M, Ezzelarab M, Dargo G, Peterson K, Masterson K, Ramsey C, Ward T, Lienesch M, Volk A, Cooper DK, Thomson AW, Kiss JE, Penedo MC, Schatten GP, Mitalipov S, Orwig KE. Spermatogonial stem cell transplantation into rhesus testes regenerates spermatogenesis producing functional sperm. Cell Stem Cell. 2012 Nov 2;11(5):715-26. doi: 10.1016/j.stem.2012.07.017. PubMed 23122294 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT02418832
Lead sponsor
Hadassah Medical Organization
Responsible party
Benjamin Reubinoff (Professor, Chairman of the Department of Obstetrics and Gynecology, Hadassah Ein Kerem, Hadassah Medical Organization) — Principal investigator
First posted
Apr 16, 2015
Start date
Jul 28, 2018
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Mar 4, 2025

Study contacts

Benjamin E. Reubinoff, MD PhD
Contact
benjaminr@ekmd.huji.ac.il
972-2-677-7485
Shelly E. Tannenbaum, MSQA
Contact
stannenbaum@hadassah.org.il
972-572-2014
Benjamin E. Reubinoff, MD PhD
principal investigator · Hadassah University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion